

**Analysis of the function and subcellular localization of
FAT/CD36 in hepatocytes and transfected cell lines of hepatic
and non-hepatic origin**

By

Nicholas Eyre B.Sc. (Hons)

THE DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY
THE SCHOOL OF MOLECULAR AND BIOMEDICAL SCIENCE
THE UNIVERSITY OF ADELAIDE



A dissertation submitted to the University of Adelaide
In candidature for the degree of
Doctor of Philosophy in the Faculty of Science
June 2007

Investigations of the function and sub-cellular localization of FAT/CD36 in hepatic and non-hepatic transfected cell lines	i
Declaration	xiv
Acknowledgements	xv
Presentations and publications from this study	xvi
Abstract	xvii
Chapter 1: Introduction	1
1.1 Class B scavenger receptors.....	1
1.2 Membrane topology and post-translational modification of FAT/CD36.....	2
1.3 FAT/CD36 ligands and distribution.....	4
1.4 CD36 and accumulation of oxLDL by macrophages: an early event in the development of atherosclerosis.....	5
1.4.1 Other mediators of oxLDL uptake by macrophages.....	7
1.4.2 Regulation of CD36 expression in macrophages.....	7
1.5 FAT/CD36 and long-chain fatty acid transport.....	8
1.5.1 Long-chain fatty acid biology.....	8
1.5.2 Passive diffusion of LCFA across the lipid bilayer.....	9
1.5.3 Facilitated LCFA transport.....	10
1.5.4 Proteins implicated in LCFA transport.....	10
1.5.4.1 FAT/CD36.....	10
1.5.4.2 FATP1.....	12
1.5.4.3 FABP _{PM}	13
1.5.4.4 Fatty acid binding proteins and fatty-acyl CoA synthetases.....	14
1.5.4.5 Caveolin-1, caveolae and lipid rafts.....	15
1.6 Animal models of FAT/CD36 deficiency and over-expression: Effects on LCFA metabolism.....	18
1.7 FAT/CD36 deficiency in humans and LCFA metabolism.....	22
1.8 Regulation of FAT/CD36 expression and activity in muscle and adipose tissue.....	23
1.8.1 Transcriptional regulation of FAT/CD36 in muscle and adipose tissue.....	23
1.8.2 Regulation of FAT/CD36 translocation to the plasma membrane of adipocytes and cardiac and skeletal myocytes.....	26
1.9 Localization of FAT/CD36 in muscle and adipose tissues.....	29

1.10 Regulation, localization and function of FAT/CD36 in the liver.....	31
1.11 SR-BI: an atheroprotective class B scavenger receptor	33
1.11.1 Membrane topology and posttranslational modification of SR-BI	35
1.11.2 SR-BI ligands and distribution	36
1.11.3 SR-BI and HDL Cholesterol Metabolism	37
1.11.4 Direct comparisons of the activity of SR-BI and FAT/CD36 and domain-swap chimeras of these receptors	44
1.11.5 In Vivo Studies of SR-BI-mediated HDL Metabolism	46
1.11.6 Regulation of hepatic SR-BI expression	49
1.11.7 Post-translational stabilization of SR-BI by the cytoplasmic adaptor PDZK1 ..	51
1.11.8 Subcellular localization of SR-BI.....	52
1.12 Prelude to the study	53
Chapter 2: Materials and Methods.....	54
2.1 Molecular Biology Techniques	54
2.1.1 Synthetic oligonucleotides	54
2.1.2 RNA extraction.....	54
2.1.3 Estimation of RNA concentration	54
2.1.4 Preparation of cDNA from mRNA by reverse transcription.....	54
2.1.5 Genomic DNA extraction.....	56
2.1.6 Polymerase Chain Reaction (PCR)	56
2.1.7 DNA sequencing	57
2.1.8 Preparation of competent bacteria for transformation.....	57
2.1.9 Transformation of competent bacteria with plasmid DNA.....	58
2.1.10 Preparation of plasmid DNA	58
2.1.11 Restriction digests of plasmid DNA.....	59
2.1.12 Agarose gel electrophoresis.....	59
2.1.13 Gel extraction of DNA	60
2.1.14 Alkaline phosphatase treatment of digested DNA	60
2.1.15 Annealing oligonucleotides for adaptor-duplex cloning.....	60
2.1.16 DNA ligation	61
2.2 Cell Culture Techniques	61
2.2.1 Tissue Culture Medium	61
2.2.2 Maintenance of Cell Lines	61
2.2.3 Cryopreservation	63
2.2.4 Resuscitation of Frozen Cells.....	63
2.2.5 Transfection.....	63
2.3 Flow Cytometry Techniques	64
2.3.1 Labelling Cell Surface Antigens	64
2.3.2 Labelling Intracellular Antigens.....	67
2.3.3 Flow Cytometric Analysis of Lipid Uptake from DiI-HDL.....	67
2.3.4 Flow Cytometric Analysis.....	68

2.4 Fluorescence Microscopy Techniques	68
2.4.1 Indirect immunofluorescence labelling	69
2.4.2 Staining Lipid Rafts with CT-B	69
2.4.3 Cellular binding and uptake of HDL ₃ -DiI	69
2.4.4 Light fluorescence microscopy	70
2.4.5 Confocal fluorescence microscopy	70
2.5 Protein Chemistry Techniques	70
2.5.1 Antibody biotinylation	70
2.5.2 Sucrose density step-gradient ultracentrifugation	71
2.5.3 Hypotonic lysis.....	71
2.5.4 Extraction of Triton-soluble proteins	72
2.5.5 Cell surface biotinylation and streptavidin-precipitation	72
2.5.6 Cell surface biotinylation and streptavidin precipitation of DRMs	73
2.5.7 Deglycosylation of proteins with <i>N</i> -glycanase (PNGase F).....	73
2.5.8 SDS-PAGE	73
2.5.9 Western blotting	75
2.5.10 Staining of cryostat sections by the indirect immunoperoxidase technique	75
2.6 Lipid Chemistry Techniques	76
2.6.1 Fractionation of Human Plasma Lipoproteins using OptiPrep	76
2.6.2 Purification of HDL ₃ by Sequential Ultracentrifugation.....	77
2.6.3 Fluorescent (DiI) Labelling of Purified HDL ₃	78
2.6.4 Assay of oleate uptake.....	78
2.6.5 Cellular lipid separation by thin layer chromatography (TLC).....	79
2.6.6 Oil Red O staining.....	79
Chapter 3: Investigations into the involvement of FAT/CD36 in LCFA uptake in transfected cell lines	81
3.1 Introduction	81
3.2 Hypotheses:	83
3.3 Generation of FAT/CD36-expressing stable cell lines.....	83
3.3.1 Generation of mammalian expression plasmid pcDNA3-FAT/CD36	83
3.3.2 Stable transfection of COS-7 and H4IIE cell lines.....	84
3.3.3 Generation of a CHO cell line in which FAT/CD36 expression can be manipulated exogenously by tetracycline	84
3.3.3.1 The ‘tet-off’ system.....	85
3.3.3.2 Generation of a tTA-expressing stable CHO cell line.....	85
3.3.3.3 Generation of a tTA-responsive FAT/CD36 expression construct	85
3.3.3.4 Stable transfection of CHO-Tet-Off 1.2 cells with the tTA-responsive plasmid pTRE2-FAT/CD36-IRES-puro 6.....	86
3.3.3.5 Dose-dependent regulation of FAT/CD36 expression by doxycycline in clone 1.2C3 of the CHO-Tet-Off 1.2~TRE-FAT/CD36 cell line	88
3.3.3.6 Time-dependent induction / repression of FAT/CD36 expression in clone 1.2C3 cells in response to doxycycline	88

3.4 Investigations into the subcellular localization of FAT/CD36 in transfected cell lines and rat liver.....	90
3.4.1 Generation of Caveolin-1-EGFP expression plasmids.....	91
3.4.2 Subcellular localization of FAT/CD36 in rat liver.....	92
3.4.2.1 Introduction.....	92
3.4.2.2 Hepatic expression of FAT/CD36 in rats.....	93
3.4.2.3 Biochemical analysis of FAT/CD36 localization to lipid rafts in rat liver ...	94
3.4.3 Subcellular localization of FAT/CD36 in transfected COS-7 cells.....	95
3.4.3.1 Biochemical analysis of FAT/CD36 localization to lipid rafts in transfected COS-7 cells.....	95
3.4.3.2 Localization of FAT/CD36 to lipid rafts/caveolae in transfected COS-7 cells, as determined by confocal fluorescence microscopy.....	96
3.4.4 Subcellular localization of FAT/CD36 in transfected H4IIE cells.....	97
3.4.4.1 Biochemical analysis of FAT/CD36 localization to lipid rafts in transfected H4IIE cells.....	97
3.4.4.2 Stable expression of caveolin-1-EGFP in H4IIE (5A) and H4IIE-FAT/CD36 (1A) cell lines.....	97
3.4.4.3 Enrichment of FAT/CD36 and caveolin-1-EGFP in DRMs prepared from co-transfected H4IIE cell lines.....	98
3.4.4.4 Localization of FAT/CD36 to lipid rafts/caveolae of transfected H4IIE cells as determined by confocal fluorescence microscopy.....	98
3.4.4.5 Localization of FAT/CD36 to lipid raft and non-raft micro-domains of the plasma membrane of transfected H4IIE cells.....	99
3.4.5 Subcellular localization of FAT/CD36 in transfected CHO cells.....	101
3.4.5.1 Biochemical analysis of FAT/CD36 localization in CHO 1.2C3 cells.....	101
3.4.5.2 Subcellular localization of FAT/CD36 in CHO 1.2C3 cells, determined by confocal fluorescence microscopy.....	102
3.5 Effects of FAT/CD36 on long-chain fatty acid uptake in transfected cell lines.....	103
3.5.1 Long-chain fatty acid uptake and metabolism by FAT/CD36-transfected H4IIE and COS-7 cell lines.....	103
3.5.1.1 Impact of FAT/CD36 over-expression on LCFA uptake by H4IIE cells....	103
3.5.1.2 The impact of FAT/CD36 expression on metabolism of oleic acid by transfected H4IIE cells.....	104
3.5.1.3 The effect of FAT/CD36 expression on neutral lipid accumulation in COS-7 cells.....	105
3.5.1.4 The impact of lipid rafts on LCFA uptake by FAT/CD36-transfected COS-7 and H4IIE cell lines.....	106
3.5.1.5 The impact of caveolin-1-EGFP expression on FAT/CD36-dependent and FAT/CD36-independent pathways of LCFA uptake.....	107
3.5.2 The influence of the level of FAT/CD36 expression on long-chain fatty acid uptake and metabolism by the CHO 1.2C3 cell line.....	107
3.5.2.1 The impact of modulation FAT/CD36 expression on oleic acid uptake by the CHO 1.2C3 cell line.....	107
3.5.2.2 The impact of the level of FAT/CD36 expression on oleic acid metabolism by the CHO 1.2C3 cell line.....	108
3.5.2.3 Possible explanations for the lack of effect of FAT/CD36 on LCFA uptake by the CHO 1.2C3 cell line.....	109
3.6 Summary.....	110

Chapter 4: Investigations into the involvement of FAT/CD36 in lipid uptake from HDL	113
4.1 Introduction	113
4.2 Hypotheses:	115
4.3 Localization of FAT/CD36, SR-BI and lipid rafts	115
4.3.1 Screening H4IIE cells for expression of SR-BI and other potential contributors to HDL-CE selective uptake.....	116
4.3.2 Localization of endogenous SR-BI with respect to FAT/CD36 and caveolin-1 in transfected H4IIE cell lines	117
4.3.3 Expression of SR-BI in rat liver	118
4.3.4 Subcellular localization of SR-BI in rat liver	119
4.4 Assessment of FAT/CD36-mediated HDL-lipid uptake in transfected cell lines ...	119
4.4.1 Preparation, analysis and labelling of HDL ₃ from human blood	120
4.4.1.1 Purification of lipoproteins using OptiPrep.....	121
4.4.1.2 Preparation of HDL ₃ by sequential ultracentrifugation.....	121
4.4.1.3 Fluorescent labelling of HDL ₃	122
4.4.2 HDL ₃ -DiI uptake by transfected cell lines	122
4.4.2.1 Uptake of HDL ₃ -DiI by transfected H4IIE cell lines	122
4.4.2.2 Kinetics of HDL ₃ -DiI uptake and the influence of FAT/CD36 and/or caveolin-1-EGFP expression.....	123
4.4.2.3 The influence of variations in the level of FAT/CD36 expression on HDL ₃ -DiI uptake in CHO 1.2C3 cells	124
4.4.2.4 The influence of FAT/CD36 expression on SR-BI-mediated HDL-lipid uptake in CHO 1.2C3 cells.....	125
4.5 Summary	126
Chapter 5: Importance of the C-terminus of FAT/CD36 for localization to the plasma membrane and activity in long-chain fatty acid uptake and metabolism	129
5.1 Introduction	129
5.2 Hypotheses:	130
5.3 Effects of C-terminal truncation on the subcellular localization of FAT/CD36	130
5.3.1 Generation of constructs encoding FAT/CD36 truncation mutants and expression in stably transfected H4IIE cells	131
5.3.2 Expression and subcellular localization of FAT/CD36del5 and FAT/CD36del10 as determined by flow cytometry	132
5.3.3 Assessment of plasma membrane expression of FAT/CD36del5 and FAT/CD36del10 by cell-surface biotinylation and streptavidin precipitation.....	133
5.3.4 Examination of the subcellular localization of FAT/CD36del5 and FAT/CD36del10 by confocal fluorescence microscopy	133

5.3.5 Association of FAT/CD36 truncation mutants with membranes in H4IIE transfectants.....	134
5.3.6 Association of FAT/CD36 truncation mutants with detergent-resistant membranes (DRMs) in H4IIE transfectants.....	135
5.3.7 Localization of FAT/CD36 truncation mutants with respect to the lipid raft marker GM ₁	136
5.3.8 Co-expression of caveolin-1-EGFP in the H4IIE-FAT/CD36del5 and H4IIE-FAT/CD36del10 cell lines.....	136
5.3.9 Subcellular localization of FAT/CD36del5 and FAT/CD36del10 with respect to caveolin-1.....	137
5.3.10 Association of FAT/CD36del5 and FAT/CD36del10 with DRMs in H4IIE cell lines co-expressing caveolin-1-EGFP.....	138
5.3.11 Effects of truncation of the C-terminus on glycosylation of FAT/CD36.....	138
5.4 Investigations of membrane attachment of the FAT/CD36 cytoplasmic C-terminus.....	139
5.4.1 Generation of DNA constructs and cell lines to investigate the importance of the cytoplasmic C-terminus of FAT/CD36 for membrane attachment and localization.....	140
5.4.2 Assessment of the subcellular localization of the EGFP-Cterm-FAT/CD36 fusion protein.....	141
5.4.3 Assessment of membrane attachment of the EGFP-Cterm-FAT/CD36 fusion protein.....	142
5.4.4 Assessment of DRM association of the EGFP-Cterm-FAT/CD36 fusion protein.....	143
5.4.5 Microscopic assessment of association of EGFP chimeras with cell membranes.....	145
5.4.6 Effect of co-expression of EGFP-Cterm-FAT/CD36 and FAT/CD36 on the levels of cell-surface FAT/CD36.....	145
5.4.7 Assessment of the contribution of the cytoplasmic N-terminus of FAT/CD36 to the receptor's localization and attachment to membranes.....	146
5.5 The impact of C-terminal truncation on FAT/CD36-dependent LCFA uptake and metabolism.....	148
5.5.1 The effect of C-terminal truncation on the FAT/CD36-dependent component of oleate uptake by transfected H4IIE cell lines.....	149
5.5.2 The effect of C-terminal truncation of FAT/CD36 on the metabolism of absorbed oleic acid in transfected H4IIE cell lines.....	150
5.6 Summary.....	150
Chapter 6: Generation of liver-specific FAT/CD36 conditional transgenic mice.....	153
6.1 Introduction.....	153
6.2 Hypotheses:.....	155
6.3 Generation and acquisition of constructs.....	155
6.3.1 Plasmid pAlb-tTA.....	155
6.3.2 Plasmid pTRE2-FAT/CD36-IRES-EGFP.....	156

6.3.3 Sequencing of pTRE2-CD36-IRES-EGFP	157
6.4 Testing of DNA constructs in vitro	157
6.4.1 Testing of pAlb-tTA and pTRE2-FAT/CD36-IRES-EGFP in an in vitro hepatocyte cell model.....	157
6.4.2 Testing of the pTRE2-FAT/CD36-IRES-EGFP plasmid in CHO-Tet-Off 1.2 cells.....	158
6.4.3 Engagement of OzGene Pty. Ltd.....	160
6.5 Generation of the transgenic mice by Ozgene.....	160
6.5.1 Introduction: Strategy for incorporation of both elements of the Tet-Off system into a single lentiviral vector	160
6.5.2 Cloning of INS-Alb-tTA-INS and TRE2-FAT/CD36-IRES-EGFP DNA fragments into a single lentiviral vector	161
6.5.3 Lentiviral Packaging.....	162
6.5.4 Lentiviral Titration	162
6.5.5 Development of a PCR-based genotyping technique.....	163
6.6 Summary	163
Chapter 7: General Discussion.....	165
7.1 The subcellular localization of FAT/CD36 and SR-BI in hepatic and non-hepatic cells.....	165
7.2 FAT/CD36-mediated uptake of long-chain fatty acids.	171
7.3 The influence of FAT/CD36 expression on lipid uptake from HDL	177
7.4 Involvement of the carboxy terminus of FAT/CD36 in maturation of the molecule, its traffic to the plasma membrane and its ability to mediate LCFA uptake in H4IIE cells	180
7.5 Summary	183
Appendix 1.....	184
Bibliography.....	187
Appendix 2.....	209

Figure:**Follows Page:**

Figure 1-1. Involvement of CD36 in cholesterol transport in macrophages.	8
Figure 1-2. Model of protein-mediated long-chain fatty acid (LCFA) transport.	8
Figure 1-3. Contraction- and insulin-stimulated translocation of FAT/CD36 and GLUT4 from intracellular depots to the plasma membrane in muscle.	27
Figure 1-4. Schematic diagram of mouse SR-BI (mSR-BI).	46
Figure 3-1. Map of plasmid pcDNA3 (Invitrogen).	83
Figure 3-2. Assessment of FAT/CD36 expression by COS-7 cell clones stably transfected with pcDNA3-FAT/CD36.	84
Figure 3-3. Assessment of FAT/CD36 expression by H4IIE cell clones stably transfected with pcDNA3-FAT/CD36.	84
Figure 3-4. Map of plasmid pTet-Off (Clontech).	85
Figure 3-5. Assessment of tTA expression by CHO cell clones stably transfected with pTet-Off.	85
Figure 3-6. Map of plasmid pTRE2 (Clontech).	85
Figure 3-7. Map of plasmid pEF-IRES-puro6.	86
Figure 3-8. Doxycycline-dependent regulation of FAT/CD36 in the heterogenous CHO- Tet-Off 1.2~TRE-FAT/CD36 cell line.	87
Figure 3-9. Assessment of FAT/CD36 expression and sensitivity of FAT/CD36 expression to doxycycline in clones of the CHO-Tet-Off 1.2~TRE-FAT/CD36 cell line.	87
Figure 3-10. Dose-dependent regulation of FAT/CD36 expression in the CHO 1.2C3 clonal cell line.	88
Figure 3-11. Dose-dependent regulation of FAT/CD36 expression in the CHO 1.2C3 cell line as determined by Western blotting.	88
Figure 3-12. Time-dependent downregulation of FAT/CD36 expression in CHO 1.2C3 cells following addition of doxycycline.	89
Figure 3-13. Time-dependent upregulation (de-repression) of FAT/CD36 expression in CHO 1.2C3 cells following removal of doxycycline.	89
Figure 3-14. Map of plasmid pEGFP-N1 (Clontech).	91
Figure 3-15. Distribution of FAT/CD36 in male and female rat liver (F344 strain).	93
Figure 3-16. Gender-biased expression of FAT/CD36 in rat liver.	93
Figure 3-17. Detection of caveolin-1 in homogenates of male and female rat liver.	94
Figure 3-18. Association of FAT/CD36 with lipid raft-derived detergent-resistant membranes (DRMs) prepared from rat liver.	94
Figure 3-19. Comparison of association of FAT/CD36 with lipid raft-derived detergent- resistant membranes (DRMs) prepared from male and female rat liver.	95
Figure 3-20. Western blot analysis of FAT/CD36 and caveolin-1 in detergent-resistant mebrane (DRM) preparations from the clonal COS-7-FAT/CD36 cell line.	95
Figure 3-21. Localization of FAT/CD36 and lipid rafts by confocal fluorescence microscopic analysis of the COS-7-FAT/CD36 cell line.	96
Figure 3-22. Localization of caveolae (caveolin-1) and lipid rafts (GM ₁) by confocal fluorescence microscopy.	96
Figure 3-23. Western blot analysis of FAT/CD36 in detergent-resistant membrane (DRM) preparations from the H4IIE-FAT/CD36 (1A) cell line.	97
Figure 3-24. Expression of FAT/CD36 and caveolin-1-EGFP in stably transfected H4IIE cell lines as determined by flow cytometric analysis.	98
Figure 3-25. Western blot analysis of FAT/CD36 and caveolin-1-EGFP in detergent- resistant membrane (DRM) preparations from transfected H4IIE cell lines.	98

Figure 3-26. Localization of FAT/CD36 and lipid rafts by confocal fluorescence microscopic analysis of the H4IIE-FAT/CD36 (1A) cell line.	99
Figure 3-27. Localization of FAT/CD36 and caveolin-1-EGFP in the H4IIE-FAT/CD36 (1A) + caveolin-1-EGFP cell line.	99
Figure 3-28. Enrichment of FAT/CD36 in lipid raft and non-raft components of the plasma membrane.	100
Figure 3-29. Western blot analysis of FAT/CD36 and caveolin-1 in detergent-resistant membrane (DRM) preparations from the CHO 1.2C3 cell line.	101
Figure 3-30. Co-localization of FAT/CD36 and lipid rafts by confocal fluorescence microscopic analysis of the CHO 1.2C3 cell line.	102
Figure 3-31. Localization of FAT/CD36 and caveolin-1-EGFP in CHO 1.2C3 cells transiently transfected with pCaveolin-1-EGFP.	102
Figure 3-32. Uptake of [¹⁴ C]-oleic acid H4IIE (5A) and H4IIE-FAT/CD36 (1A) cell lines.	104
Figure 3-33. Incorporation of [¹⁴ C]-oleate into complex cellular lipids in H4IIE (5A) and H4IIE-FAT/CD36 (1A) cell lines.	104
Figure 3-34. Neutral lipid staining of COS-7-pcDNA3 and COS-7-FAT/CD36 cell lines.	105
Figure 3-35. FAT/CD36 expression in COS-7 cells increases their size and complexity.	105
Figure 3-36. The impact of depletion of lipid rafts with methyl- β -cyclodextrin on [¹⁴ C]-oleic acid uptake and surface expression of FAT/CD36 in stably transfected COS-7 and H4IIE cell lines.	106
Figure 3-37. The effect of caveolin-1 expression on cellular [¹⁴ C]-oleic acid uptake by transfected H4IIE cell lines.	107
Figure 3-38. FAT/CD36 expression levels do not correlate with cellular [¹⁴ C]-oleate uptake in CHO 1.2C3 cells.	108
Figure 3-39. FAT/CD36 expression levels do not correlate with incorporation of [¹⁴ C]-oleate into complex lipids in CHO 1.2C3 cells.	109
Figure 3-40. FAT/CD36 in CHO 1.2C3 cells may be inappropriately glycosylated.	110
Figure 4-1. RT-PCR analysis of gene expression in H4IIE cells.	117
Figure 4-2. Western analysis of endogenous SR-BI expression in transfected H4IIE cell lines.	117
Figure 4-3. SR-BI is not strongly associated with lipid raft-derived detergent-resistant membranes (DRMs) in H4IIE cell lines.	117
Figure 4-4. Subcellular localization of endogenous SR-BI with respect to FAT/CD36 and caveolin-1-EGFP in transfected H4IIE cell lines.	118
Figure 4-5. Expression of SR-BI in rat liver is not significantly influenced by gender.	119
Figure 4-6. SR-BI is not strongly associated with lipid raft-derived detergent-resistant membranes (DRMs) in rat liver.	119
Figure 4-7. Preparation of lipoproteins from human plasma using OptiPrep (iodixanol) density gradient ultracentrifugation.	121
Figure 4-8. Preparation of highly purified HDL ₃ by sequential ultracentrifugation.	122
Figure 4-9. HDL ₃ -DiI binding and uptake by transfected H4IIE cell lines.	122
Figure 4-10. Time-course of HDL ₃ -DiI uptake by transfected H4IIE cell lines.	123
Figure 4-11. Saturation curves of HDL ₃ -DiI binding and uptake by H4IIE (5A) and H4IIE-FAT/CD36 (1A) cell lines.	124
Figure 4-12. The correlation between FAT/CD36 expression levels and HDL ₃ -DiI uptake.	124
Figure 4-13. FAT/CD36 expression does not cooperatively enhance SR-BI mediated HDL ₃ -DiI uptake in CHO 1.2C3 cells.	125

Figure 5-1. Schematic diagrams of wildtype FAT/CD36 and carboxy-terminal truncation mutants.	131
Figure 5-2. Map of plasmid pcDNA6/V5-His (Invitrogen).	131
Figure 5-3. Truncation of the C-terminal ten amino acid residues of FAT/CD36 results in its cytosolic retention.....	132
Figure 5-4. Truncation of the C-terminal ten amino acid residues of FAT/CD36 results in its cytosolic retention.....	133
Figure 5-5. Localization of FAT/CD36 and FAT/CD36 truncation mutants by confocal laser scanning microscopy.....	134
Figure 5-6. Membrane association of wildtype FAT/CD36 and C-terminus truncation mutants.	134
Figure 5-7. C-terminal truncation does not prevent association of FAT/CD36 with detergent-resistant membranes.	135
Figure 5-8. C-terminal truncation of FAT/CD36 inhibits its association with detergent-resistant membranes.	136
Figure 5-9. Subcellular localization of FAT/CD36del5 and FAT/CD36del10 with respect to the lipid raft marker GM ₁	136
Figure 5-10. Detection of FAT/CD36 at the cell surface and within the cytosol of H4IIE (5A), H4IIE-FAT/CD36 (1A), H4IIE-FAT/CD36del5 and FAT/CD36del10 cells stably expressing caveolin-1-EGFP.	137
Figure 5-11. Subcellular localization of FAT/CD36del5 and FAT/CD36del10 with respect to caveolin-1-EGFP.	137
Figure 5-12. Western blot analysis of FAT/CD36 in detergent-resistant membrane (DRM) preparations from stably transfected H4IIE cell lines.	138
Figure 5-13. Deglycosylation resolves the apparent difference in molecular weights between FAT/CD36del10 and wildtype FAT/CD36.....	139
Figure 5-14. Map of plasmid pEGFP-C1 (Clontech).	140
Figure 5-15. The influence of the cytoplasmic C-terminus of FAT/CD36 on the subcellular localization of an EGFP-fusion reporter.	141
Figure 5-16. The C-terminus of FAT/CD36 confers membrane association to EGFP.	142
Figure 5-17. The C-terminus of FAT/CD36 reduces the detergent-solubility of an EGFP fusion protein reporter.	143
Figure 5-18. Association of EGFP-chimeric proteins with DRMs in transfected H4IIE cells.....	144
Figure 5-19. Association of EGFP-chimeric proteins with DRMs in transfected COS-7 cells.....	144
Figure 5-20. Microscopic analysis of the detergent-solubility of EGFP-chimeric proteins in transfected H4IIE cells.	145
Figure 5-21. Expression of EGFP-Cterm-FAT/CD36 does not inhibit cell-surface expression of FAT/CD36 in H4IIE transfectants.	146
Figure 5-22. The cytoplasmic N-terminus of FAT/CD36 is not sufficient to confer membrane attachment to EGFP.....	147
Figure 5-23. The cytoplasmic N-terminus of FAT/CD36 is not sufficient to decrease the detergent-solubility of an EGFP fusion protein reporter.	147
Figure 5-24. The cytoplasmic N-terminus of FAT/CD36 does not (appreciably) alter the subcellular localization of an EGFP fusion protein reporter.	148
Figure 5-25. Comparison of oleate uptake by H4IIE (5A), H4IIE-FAT/CD36 (1A), H4IIE-FAT/CD36del5 and H4IIE-FAT/CD36del10 cell lines.	149
Figure 6-1. A; Map of plasmid pAlb-tTA.	155
Figure 6-2. Diagnostic restriction digest of pTRE2-FAT/CD36-IRES-EGFP clones.	157

Figure 6-3. RT-PCR analysis of FAT/CD36 and tTA gene expression in H4IIE cells co-transfected with pAlb-tTA and pTRE2-FAT/CD36-IRES-EGFP.....	158
Figure 6-4. Doxycycline-sensitive expression of EGFP in CHO-Tet-Off 1.2 cells transfected with pTRE2-FAT/CD36-IRES-EGFP.....	159
Figure 6-5. Doxycycline-sensitive expression of FAT/CD36 and EGFP in CHO 1.2C3 cells transfected with pTRE2-FAT/CD36-IRES-EGFP.....	159
Figure 6-6. Doxycycline-sensitive expression of FAT/CD36 and EGFP in CHO 1.2C3 cells transfected with pTRE2-FAT/CD36-IRES-EGFP.....	160
Figure 6-7. Primers employed by Ozgene.....	161
Figure 6-8. Southern blot analysis of infectivity of lentiviral vectors.....	163
Figure 6-9. Development of a PCR-based technique for detection of integrated FAT/CD36 and tTA transgenes.....	163

Table 1-1. Mutational analysis of mouse SR-BI	34
Table 2-1. Oligonucleotides	55
Table 2-2. Cell culture media	62
Table 2-3. Primary antibodies and their application	65
Table 2-4. Conjugated secondary antibodies and their application.....	66
Table 5-1. Incorporation of [¹⁴ C]-oleate into complex cellular lipids by transfected H4IIE cell lines.....	151

DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis being made available in the University Library.

The author acknowledges that copyright of published works contained within this thesis (as listed below) resides with the copyright holder/s of those works.

Nicholas Eyre, B.Sc. (hons).

Acknowledgements

First of all, I would like to thank my supervisors Profs. Graham Mayrhofer and Les Cleland for their supervision and guidance over the years. I am particularly grateful to Graham for giving me the freedom and encouragement to explore new areas and techniques, even when they strayed from the initial aims of the project. I am also very grateful for the meticulous review and constructive criticism of my reports, presentations and the thesis. All of the lessons learnt in your lab should stand me in good stead for the future.

I would also like to thank all of the members of the Mayrhofer laboratory and the Arthritis Research Laboratory, past and present, who have offered their friendship and technical expertise over the years. Particularly big thanks to Beck, Gorjana, Wendy and Minky for being great friends and co-workers, during the good times and the bad. Thanks to Mahin and Llew for their friendship and generosity with technical help and reagents. Outside of the lab, thanks also must go to Jocelyn, Tony, Shaun, Adriana, Mick, James, Damien, Dan, Michael, Karla, Marina, Meredith, Sandy and Alan for generosity with advice and/or reagents along the way. Thanks also to the people who help the whole building 'tick'; Garry, Chris, Serge, Shirley, Adriana, Judy, John, Ros and Jan. Finally, big thanks to my friends in other labs who have helped me to maintain some sanity at work; Paul, Damian, Tom, Brock, Iain, Jane, Scott, Sarah, Erin, Fran and anyone else I forgot, you know who you are.

I would also like to thank my parents and sister for their love, encouragement and patience throughout these years. Finally big thanks must go to my wife Melina for her love and fantastic support throughout.

Presentations and publications from this study

Conference Presentations:

Eyre, N.S., L. Cleland, G. Mayrhofer. Uptake and incorporation of long-chain fatty acids into cellular lipids in FAT/CD36 transfected cell lines. *7th Congress of the International Society for the Study of Fatty Acids & Lipids incorporating the 6th International Congress on Essential Fatty Acids and Eicosanoids & PUFA in Maternal and Infant Health Annual Scientific Meetings*. Cairns, Australia. 2006 (poster presentation)

Eyre, N.S., L. Cleland, G. Mayrhofer. The localization and activity of FAT/CD36 is influenced by its carboxy-terminal cytoplasmic tail. *Heart Foundation Conference and Scientific Meeting: Cardiovascular Disease in the 21st Century: Shaping the Future*. Sydney, Australia. 2006 (poster presentation)

Eyre, N.S., L. Cleland, G. Mayrhofer. Factors influencing CD36-mediated long-chain fatty acid uptake. *Australian Society for Medical Research: Annual Scientific Meeting*. Adelaide, Australia. 2005.

Eyre, N.S., L. Cleland, G. Mayrhofer. Cellular localization of CD36 and its role in lipid uptake. *Australian Society for Medical Research: Annual Scientific Meeting*. Adelaide, Australia. 2004.

Publications:

Eyre, N.S., Cleland L.G., Tandon, N.N., Mayrhofer G (2007). Importance of the carboxyl terminus of FAT/CD36 for plasma membrane localization and function in long-chain fatty acid uptake. *J Lipid Res.* 48(3): 528-42. (see Appendix 2)

Eyre, N.S., Cleland L.G., Mayrhofer G (2007). Inducible expression of FAT/CD36 does not enhance oleic acid uptake by CHO cells. *Manuscript in preparation*.

Abstract

The class B scavenger receptor CD36, or fatty acid translocase (FAT), is an 88 kDa plasma membrane glycoprotein that is the founding member of the class B scavenger receptor family. It has a number of natural ligands and has different functions at various locations in the body. It contributes to adhesion of platelets via its binding to thrombospondin-1. In monocytes and macrophages, it contributes to recognition and phagocytosis of apoptotic cells and it mediates the binding and uptake of oxidatively damaged low-density lipoproteins (oxLDL). In adipose and muscle tissues, FAT/CD36 mediates high-affinity binding and uptake of long-chain fatty acids (LCFAs) and is therefore a key regulator of lipid storage (particularly in adipocytes) and mitochondrial beta oxidation (particularly in muscle). Interestingly FAT/CD36 also binds native lipoproteins (including high-density lipoproteins [HDL]) with high affinity *in vitro*, although the physiological significance of this is unclear at present.

Expression of FAT/CD36 by hepatocytes has not been recognised until recently, mainly because it is gender-regulated in both humans, and rats. However, the primary function of FAT/CD36 in the liver is unknown. The work described in this thesis has used various transfected cell lines to examine the possibility that FAT/CD36 contributes to hepatic LCFA uptake and/or the uptake of cholesteryl esters (and other lipids) from HDL. The subcellular localization of FAT/CD36 has been explored in rat liver and in cell lines of hepatic and non-hepatic origin, especially with respect to its association with specialized plasma membrane lipid raft microdomains known as caveolae. Furthermore, the importance of the cytoplasmic carboxyl-terminus of FAT/CD36 in both subcellular localization of the molecule and its activity as a LCFA transporter has been examined using truncated mutants and chimeric variants of FAT/CD36.

The results indicate that FAT/CD36 contributes to LCFA uptake by hepatocyte-derived cell lines. In these cells it resides in both non-raft and lipid raft domains of the plasma membrane that may not always include caveolae. The studies also indicate that the cytoplasmic C-terminus of FAT/CD36 contributes to the attachment of FAT/CD36 to membranes, including raft-derived detergent-resistant membranes. This domain is necessary also for correct targeting of the receptor to the plasma membrane and for its activity as a LCFA transporter. Finally, DNA constructs have been prepared and tested,

with the objective of producing transgenic mice in which expression of FAT/CD36 can be induced and over-expressed specifically in the liver. This model could be used to confirm whether FAT/CD36 has a role as a LCFA transporter in the liver and to explore whether it has additional significance as a hepatic transporter of HDL-derived cholesteryl esters or as a scavenger of oxidised LDL.